Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy (RESTORE2)

23. března 2017 aktualizováno: GlaxoSmithKline

Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures

This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs).

Přehled studie

Postavení

Dokončeno

Podmínky

Detailní popis

This Phase 3 study is being conducted in Europe, Israel, Australia, and South Africa to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs). The primary objective is to demonstrate a superior change in total partial seizure frequency for four weeks from baseline to the double-blind period. The proportion of responders (greater than or equal to 50% reduction in seizure frequency for four weeks from baseline to the double-blind period) will also be evaluated.

Typ studie

Intervenční

Zápis (Aktuální)

539

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • New South Wales
      • Camperdown, New South Wales, Austrálie, 2050
        • Royal Prince Alfred Hospital
    • Queensland
      • Maroochydore, Queensland, Austrálie, 4558
        • North Coast Neurology Centre
    • Victoria
      • Clayton, Victoria, Austrálie, 3168
        • Monash Medical Centre
      • Parkville, Victoria, Austrálie, 3050
        • Royal Melbourne Hospital
      • West Heidelberg, Victoria, Austrálie, 3084
        • Austin & Repatriation Medical Centre
      • Antwerp, Belgie, 2020
        • A. Z. Middelheim -- Department of Neurology
      • Brugge, Belgie, 8000
        • AZ Sint-Jan
      • Leuven, Belgie, 3000
        • Universitaire Ziekenhuizen Gasthuisberg -- Department Neurology
      • Ottignies, Belgie, 1340
        • Centre Neurologique William Lennox
      • Rennes Cedex, Francie, 35033
        • CHU Pontchaillou
      • Strasbourg, Francie, 67 67091
        • Hôpital Civil de Strasbourg
      • Tain L'Hermitage, Francie, 26 26600
        • Centre Medical de La Teppe
    • Lyonnais
      • Lyon, Lyonnais, Francie, 69003
        • Hopital Neurologique Pierre Wertheimer
      • Ashkelon, Izrael, 78306
        • Barzilai Medical Center
      • Beer Yaakov, Izrael, 70300
        • Assaf Harofeh Medical Center
      • Haifa, Izrael, 31096
        • Rambam Medical Center
      • Holon, Izrael, 58100
        • Wolfson Medical Center
      • Nahariya, Izrael, 22100
        • Western Galilee Hospital
      • Ramat Gan, Izrael, 52621
        • Chaim Sheba Medical Center
      • Rechovot, Izrael, 76100
        • Kaplan Medical Center
      • Tel Aviv, Izrael, 64239
        • Tel-Aviv Sourasky Medical Center
      • Cape Town, Jižní Afrika, 7550
        • Panorama Medi-Clinic
    • East Cape
      • Port Elizabeth, East Cape, Jižní Afrika, 6001
        • Triple M Research
    • Gauten
      • Johannesburg, Gauten, Jižní Afrika, 2193
        • Johannesburg Hospital
    • Gauteng
      • Bloemfontein, Gauteng, Jižní Afrika, 9300
        • University of the Free State
      • Pretoria, Gauteng, Jižní Afrika, 0041
        • Wilgers MR & Medical Centre
      • Sunninghill, Gauteng, Jižní Afrika, 2157
        • Sunninghill & Kopano Clinical Trials
    • KwaZulu-Natal
      • Durban, KwaZulu-Natal, Jižní Afrika, 4091
        • Inkosi Albert Luthuli Central Hospital
    • West Cape
      • Belville, West Cape, Jižní Afrika, 7531
        • Carl Bremer Hospital
    • Western Cape
      • Cape Town, Western Cape, Jižní Afrika, 7925
        • Groote Schuur Hospital
      • Budapest, Maďarsko, 1145
        • Országos Idegsebészeti Tudományos Intézet
      • Budapest, Maďarsko, 1021
        • Natl. Inst. of Psychiatry and Neurology
      • Bonn, Německo, D-53105
        • University of Bonn -- Department for Epileptplogy
      • Erlangen, Německo, BY 91054
        • Zentrum Epilepsie Erlangen (ZEE) der Universitaet Erlangen
      • Goettingen, Německo, NI 37075
        • Georg-August-Universitaet Goettingen
      • Mainz, Německo, RP 55101
        • Universitaetsklinik Mainz Neurologische Klinik
      • Marburg, Německo, HE 35033
        • Universitaet Giessen / Marburg Neurologie
      • Munich, Německo, BY 80333
        • Theatinerstrasse 44
      • Ulm, Německo, BW 89081
        • Universitaetsklinikum Ulm
      • Bialystok, Polsko, 15-420
        • NZOZ Przychodnia Internistyczno - Stomatologiczna "Kendron"
      • Gdansk, Polsko, 80-803
        • Wojewodzki Szpital Specjalistyczny im.Mikolaja Kopernika
      • Katowice, Polsko, 40-752
        • Katedra i Klinika Neurologii Slaskiej Akademii Medycznej
      • Lublin, Polsko, 20-718
        • WSS im.Kardynala S. Wyszynskiego
      • Warsaw, Polsko, 02-957
        • Instytut Psychiatrii i Neurologii II Oddzial Neurologii
      • Warsaw, Polsko, 03-464
        • Prywatna Wielospecjalistyczna Lecznica Medyczna "Zycie"
    • Plock
      • Padlewskiego 4, Plock, Polsko, 09-402
        • Specjalistyczna Przychodnia Lekarska Medikard
      • Kazan, Ruská Federace, 420048
        • Interregional Clinical Diagnostic Centre
      • Moscow, Ruská Federace, 117049
        • City hospital # 1
      • Moscow, Ruská Federace, 119021
        • Clinic of Nervous Diseases of Sechenov's Moscow Med. Academy
      • Moscow, Ruská Federace, 121374
        • District Antiepileptic Centre City Clinical Hospital # 71
      • St. Petersburg, Ruská Federace, 194044
        • Military Medical Academy n.a. S.M.Kirov
      • St. Petersburg, Ruská Federace, 197022
        • St.Petersburg State Medical University n.a. I.P.Pavlov
      • Blackpool, Spojené království, LANARK FY3 8BP
        • Fylde Coast Hospital
      • Glasgow, Spojené království, G11 6NT
        • Western Infirmary (Epilepsy)
      • Liverpool, Spojené království, L9 7LJ
        • Walton Centre for Neurology & Neurosurgery
      • London, Spojené království, GT LON E1 1BB
        • Royal London Hospital
    • Mersyd
      • Middlesbrough, Mersyd, Spojené království, T&W TS4 3BW
        • The James Cook University Hospital
    • Maryland
      • Bethesda, Maryland, Spojené státy, 20817
        • Mid-Atlantic Epilepsy and Sleep Center
    • Texas
      • Dallas, Texas, Spojené státy, 75230
        • Neurological Clinic-Texas
      • Dnepropetrovsk, Ukrajina, 49616
        • Psychosomatic Center of Dnepropetr. Regional Clinic
      • Kharkiv, Ukrajina, 61022
        • Kharkiv State Medical University
      • Kharkov, Ukrajina, 61068
        • Institute of Neurology, Psychiatry and Narcology of AMS, Ukr
      • Kiev, Ukrajina, 04080
        • Epilepsy Center of Municipal Clinical Psychoneurological Hospital
      • Odessa, Ukrajina, 65025
        • Odessa regional clinical Hospital
      • Barcelona, Španělsko, 08025
        • Hospital de La Santa Creu i Sant Pau
      • Bilbao, Španělsko, 48903
        • Hospital De Cruces
      • Granada, Španělsko, 18013
        • Hosp. Virgen de las Nieves
      • Madrid, Španělsko, 28034
        • Hospital Ruber Internacional de Madrid
      • San Sebastian, Španělsko, 20014
        • Hosp de Donostia
      • Zaragoza, Španělsko, 50009
        • Hosp. Clinico Univ. Lozano Blesa

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 75 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Diagnosis of refractory epilepsy with simple or complex partial onset seizures with or without secondary generalization
  • 28-day partial seizure frequency rate of four or more partial seizures over the 8-week baseline phase
  • Currently treated with up to three established AEDs
  • Vagal Nerve Stimulator may be included

Exclusion Criteria:

  • Existing medical or psychiatric condition which could affect patient's health or compromise ability to participate in the study
  • Clinically significant abnormalities on physical exam, vital signs, ECG, or liver function tests
  • Impaired renal function (creatinine clearance less than 50 mL/minute)
  • Evidence of progressive central nervous disease, lesion, or encephalopathy
  • History of primary generalized seizures
  • History of clustering or flurries or status epilepticus within 12 months of study entry

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Komparátor placeba: Placebo
Perorální tableta.
Experimentální: Retigabine 600 mg
Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
Ostatní jména:
  • GKE-841
  • D-23129
Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
Ostatní jména:
  • GKE-841
  • D-23129
Experimentální: Retigabine 900 mg
Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
Ostatní jména:
  • GKE-841
  • D-23129
Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
Ostatní jména:
  • GKE-841
  • D-23129

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)
Časové okno: Baseline (Week -7 through Week 0), DB Phase (Week 1 through Week 16)
28-day total PS (PSs [also called focal seizures] are seizures limited to a specific area of the brain) frequency in the BL period = (Number [No.] of total PSs reported in the BL period divided by the No. of days of available total PS data in the BL period) x 28 days. 28-day total PS frequency in the DB period = (No. of total PSs reported in the DB period divided by the No. of days of available total PS data in the DB period) x 28 days. Percent change = ([value in the DB period minus value at BL] divided by the BL value) x 100%. Negative valu es indicate a reduction in seizure frequency.
Baseline (Week -7 through Week 0), DB Phase (Week 1 through Week 16)
Number of Participants Classified as Responders and Non-responders During the Maintenance Phase
Časové okno: Week 5 through Week 16
Responders were participants with at least a 50% reduction in the 28-day total partial seizure frequency in the Maintenance Phase as compared to the Baseline period.
Week 5 through Week 16

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number of Participants Who Were Responders and Non-responders During the DB Phase
Časové okno: Week 1 through Week 16
Responders were participants with at least a 50% reduction in the 28-day total partial seizure frequency in the DB Phase as compared to the Baseline period. Participants without any post-baseline data were considered non-responders.
Week 1 through Week 16
Percent Change From Baseline (BL) in the 28-day Total Partial Seizure Frequency During the Maintenance Phase
Časové okno: Baseline (Week -7 through Week 0), Week 5 through Week 16
28-day total partial seizure frequency in the BL period = (No. of total partial seizures reported in the BL period divided by the No. of days of available total partial seizure data in the BL period) x 28 days. 28-day total partial seizure frequency in the Maintenance Phase = (No. of total partial seizures reported in the Maintenance Phase divided by the No. of days of available total partial seizure data in the same phase) x 28 days. Percent change = (value in the Maintenance Phase minus value at BL divided by the BL value) x 100%. Negative values indicate a reduction in seizure frequency.
Baseline (Week -7 through Week 0), Week 5 through Week 16
Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories
Časové okno: Baseline (Week -7 through Week 0), Week 1 through Week 16
Participants who experienced a reduction from Baseline in the 28-day total partial seizure frequency were categorized as having a reduction of 75-100%, 50-<75%, 25-<50%, or <25%, in addition to having no reduction. This quartile cutting was specified in the study protocol. Participants without any post-baseline data are included in the "No reduction" category.
Baseline (Week -7 through Week 0), Week 1 through Week 16
Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the DB Phase (Titration and Maintenance Phases) by Indicated Decile Reduction and Increase Categories
Časové okno: Baseline (Week -7 through Week 0), Week 1 through Week 16
Participants who experienced a reduction from Baseline in the 28-day total partial seizure frequency were categorized in decile cutting, i.e., reduction categories of 90-100%, 80-<90%, 70-<80%, 60-<70%, 50-<60%, 40-<50%, 30-<40%, 20-<30%, 10-<20%, >0-<10%, and increase categories of 0-10%, >10-20%, >20-30%, >30% (FDA endpoint). Participants without any post-baseline data were included in the category 0-10% increase category.
Baseline (Week -7 through Week 0), Week 1 through Week 16
Number of Participants With the Indicated Reduction From Baseline in the 28-day Total Partial Seizure Frequency During the Maintenance Phase
Časové okno: Baseline (Week -7 through Week 0), Week 5 through Week 16
Participants who experienced a reduction from Baseline in the 28-day total partial seizure frequency were categorized as having a >75%, a 50-75%, or a <50% reduction, in addition to having no reduction (EMEA endpoint).
Baseline (Week -7 through Week 0), Week 5 through Week 16
Number of Participants Who Experienced the Indicated Level of Exacerbation and Reduction in the 28-day Total Partial Seizure Frequency From Baseline During the Maintenance Phase
Časové okno: Baseline (Week -7 through Week 0), Week 5 through Week 16
Participants who experienced an exacerbation from Baseline in the 28-day total partial seizure frequency were categorized as having a 0-25% or a >25% increase (EMEA endpoint). The number of participants experiencing a >0% reduction from Baseline in the 28-day total partial seizure frequency are also presented.
Baseline (Week -7 through Week 0), Week 5 through Week 16
Number of Participants Reporting New Seizure Types in the Indicated Categories During the DB Phase (Titration and Maintenance Phases) That Were Not Reported at Baseline
Časové okno: Baseline (Week -7 through Week 0), Week 1 through Week 16
New seizure types included those seizures which were not reported by any participant at Baseline.
Baseline (Week -7 through Week 0), Week 1 through Week 16
Number of Participants Who Were Seizure-free During the DB Phase (Titration and Maintenance Phases)
Časové okno: Week 1 through Week 16
Participants were considered to be seizure-free if they had not reported any seizures during the DB treatment period (Weeks 1-18). For a participant to be seizure free during the DB Phase, the participant had to be seizure free both Week 7 to Week 18 and Week 1 to Week 6. A participant could be seizure free Week 7 to Week 18 (during the Maintenance Phase), but not seizure free Week 1 to Week 6. Hence, there are fewer participants being reported as seizure free from Week 1 to Week 18 than from Week 7 to Week 18.
Week 1 through Week 16
Number of Participants Who Were Seizure-free During the Maintenance Phase
Časové okno: Week 5 through Week 16
Participants were considered to be seizure-free if they had not reported any seizures during the Maintenance Phase.
Week 5 through Week 16
Percentage of Seizure-free Days During the DB Phase (Titration and Maintenance Phases)
Časové okno: Week 1 through Week 16
A seizure-free day was a day without any seizures. For a participant to be seizure free during the DB Phase, the participant had to be seizure free both Week 7 to Week 18 and Week 1 to Week 6. A participant could be seizure free Week 7 to Week 18 (during the Maintenance Phase), but not seizure free Week 1 to Week 6. Hence, there are fewer participants being reported as seizure free from Week 1 to Week 18 than from Week 7 to Week 18. The percentage of seizure-free days was calculated as the total number of days without seizures in the DB period divided by the number of days in DB period x 100%.
Week 1 through Week 16
Percentage of Seizure-free Days During the Maintenance Phase
Časové okno: Week 5 through Week 16
A seizure-free day was a day without any seizures. The percentage of seizure-free days was calculated as the total number of days without seizures in the Maintenance Phase divided by the number of days in the Maintenance Phase x 100%.
Week 5 through Week 16
Clinical Global Impression-Improvement (CGI-I) Score at the End of the Maintenance Phase
Časové okno: Week 16/end of treatment phase
Clinical Global Impression of Improvement (CGI-I) is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the treatment. Scores on the scale are rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
Week 16/end of treatment phase
Patient Global Impression (PGI) Score at the End of the Maintenance Phase
Časové okno: Week 16/end of treatment phase
PGI is a participant-rated scale of improvement that was administered at the end of the Maintenance Phase in order to assess the participant's impression of his or her own improvement. PGI assessments were scored using a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
Week 16/end of treatment phase
Quality of Life Assessed by Quality of Life in Epilepsy-Problems Questionnaire (QOLIE-31-P) at BL (Week 0) and Weeks 4, 8, and 16
Časové okno: End of Baseline (Week 0), Weeks 4, 8, and 16
The QOLIE-31-P is a 31-item questionnaire evaluating a participant's QOL perception in 7 domains: seizure worry, emotional well being, energy/fatigue, cognitive functioning, medication effects, social functioning, overall QOL. Precoded numeric values for some domains are such that a higher number reflects a more favorable health state; others are such that a higher number reflects a less favorable state. Precoded values are first converted to 0-100 point scores; higher converted scores always reflect better QOL. The overall score is derived by weighting and then summing the 7 domain scores.
End of Baseline (Week 0), Weeks 4, 8, and 16
Number of Participants Whose Clinical Laboratory Values Were Deemed an Adverse Event by the Investigator (>=2% in Any Treatment Arm)
Časové okno: Week 1 through Week 16
Clinically important changes in laboratory values were to be reported as an adverse event if they met one of the following criteria: (1) intervention required; (2) change in dose of study drug required; (3) other treatment/therapy required; (4) association with other diagnoses.
Week 1 through Week 16
Number of Participants Who Reported the Indicated Renal and Urinary Disorder Adverse Events at a Frequency Threshold of 2% (in Any Treatment Arm)
Časové okno: Week 1 through Week 16
A summary of the adverse events classified as renal or urinary disorders and in which at least 2% (rounded to an integer) of participants in any treatment arm reported during the study is presented.
Week 1 through Week 16
Change From Baseline in Post-void Residual Urine Volume at Weeks 8 and 16 of the Maintenance Phase
Časové okno: Baseline (Week -7 through 0), Weeks 8 and 16
Post-void residual (PVR) urine refers to the amount of urine remaining in the bladder after normal urination. To investigate the possible effects of retigabine on bladder function, all participants underwent post-void residual bladder ultrasound at Baseline and during the Maintenance Phase. The PVR bladder ultrasound was performed by a urologist, a qualified ultrasound technician, or a qualified study nurse who was certified to do PVR bladder ultrasound. Change from Baseline in PVR residual volume was calculated as the values at Week 10 and Week 16 minus the value at Baseline.
Baseline (Week -7 through 0), Weeks 8 and 16
Number of Participants With a >=7% Increase in Body Weight During Weeks 2 and 4 of theTitration Phase and Weeks 6, 8, 12, and 16 of the Maintenance Phase
Časové okno: Weeks 2 and 4 of Titration Phase and Weeks 6, 8, 12, and 16 of Maintenance Phase
The number of participants with recorded weight gain of >=7% over their baseline weight was measured.
Weeks 2 and 4 of Titration Phase and Weeks 6, 8, 12, and 16 of Maintenance Phase

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. prosince 2005

Primární dokončení (Aktuální)

1. dubna 2008

Dokončení studie (Aktuální)

1. dubna 2008

Termíny zápisu do studia

První předloženo

6. října 2005

První předloženo, které splnilo kritéria kontroly kvality

6. října 2005

První zveřejněno (Odhad)

10. října 2005

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

21. dubna 2017

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

23. března 2017

Naposledy ověřeno

1. března 2017

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Studijní data/dokumenty

  1. Protokol studie
    Identifikátor informace: VRX-RET-E22-302
    Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
  2. Soubor dat jednotlivých účastníků
    Identifikátor informace: VRX-RET-E22-302
    Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
  3. Formulář komentované zprávy o případu
    Identifikátor informace: VRX-RET-E22-302
    Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
  4. Zpráva o klinické studii
    Identifikátor informace: VRX-RET-E22-302
    Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
  5. Plán statistické analýzy
    Identifikátor informace: VRX-RET-E22-302
    Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
  6. Specifikace datové sady
    Identifikátor informace: VRX-RET-E22-302
    Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
  7. Formulář informovaného souhlasu
    Identifikátor informace: VRX-RET-E22-302
    Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit